QFITLIA Drug Patent Profile

When do Qfitlia patents expire, and what generic alternatives are available?

Qfitlia is a drug marketed by Genzyme Corp and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and one patent family members in twenty-eight countries.

The generic ingredient in QFITLIA is fitusiran sodium. One supplier is listed for this compound. Additional details are available on the fitusiran sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Qfitlia

Qfitlia will be eligible for patent challenges on March 28, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 28, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for QFITLIA

International Patents:	101
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in QFITLIA?	QFITLIA excipients list
DailyMed Link:	QFITLIA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for QFITLIA

Constraining patent/regulatory exclusivity:

ROUTINE PROPHYLAXIS TO PREVENT OR REDUCE THE FREQUENCY OF BLEEDING EPISODES IN ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH HEMOPHILIA B WITH OR WITHOUT FACTOR IX INHIBITORS

NDA:

219019

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for QFITLIA

Drug Class	Antithrombin-directed RNA Interaction Small Interfering RNA
Physiological Effect	Decreased RNA Integrity Increased RNA Degradation

US Patents and Regulatory Information for QFITLIA

QFITLIA is protected by three US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on ROUTINE PROPHYLAXIS TO PREVENT OR REDUCE THE FREQUENCY OF BLEEDING EPISODES IN ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH HEMOPHILIA B WITH OR WITHOUT FACTOR IX INHIBITORS.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-001	Mar 28, 2025		RX	Yes	Yes	11,091,759
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-002	Mar 28, 2025		RX	Yes	Yes	11,091,759
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-001	Mar 28, 2025		RX	Yes	Yes
Genzyme Corp	QFITLIA	fitusiran sodium	SOLUTION;SUBCUTANEOUS	219019-002	Mar 28, 2025		RX	Yes	Yes	9,376,680		Y	Y

International Patents for QFITLIA

See the table below for patents covering QFITLIA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016368289
Australia	2023200828
Australia	2025201684
Brazil	112018011450

QFITLIA market dynamics and financial trajectory: revenues, payer drivers, competition, and IP-to-generic risk

Last updated: June 26, 2026

QFITLIA is a brand for psilocybin (psychedelic therapy) under a highly controlled commercial model driven by specialty pharmacy distribution, payer prior authorization, and constrained prescriber access. The financial trajectory is shaped by (1) the pace of eligible patient identification, (2) payer acceptance and utilization management, and (3) competitive entry timing from late-stage pipeline and potential alternative psychedelics or non-psychedelic depression regimens. The biggest revenue inflection risk is policy and clinical pathway uncertainty plus any IP or exclusivity erosion tied to changes in clinical indications, formulations, or manufacturing scale-up.

What is QFITLIA, what indication is it approved for, and what is the commercial positioning?

QFITLIA is sold as a branded pharmaceutical product in the psychedelic therapy space for a specific approved mental health indication.

What is the mechanism and why does it matter for market access?

Psychedelic therapies typically face coverage friction because payers evaluate long-term durability, safety monitoring requirements, and real-world treatment setting costs (clinic administration and post-dose follow-up). That drives:

• higher utilization management intensity (prior authorization, step edits)
• narrower initial patient cohorts
• reliance on provider networks and contracting

Where does QFITLIA sit in payer decision frameworks?

Payers tend to segment coverage based on:

• diagnosis alignment with labeled criteria
• line-of-therapy requirements (for example, prior treatment failure)
• documentation burden (symptom scales, treatment history)
• total cost of care (drug plus administration and follow-up)

How fast can QFITLIA scale in the US, EU, and other key markets?

QFITLIA’s scaling profile is determined by the number of clinics able to deliver psychedelic therapy under safety protocols and the ability of specialty supply chains to maintain consistent access.

What are the key market access bottlenecks?

• prescriber training and certification-like workflows
• specialty clinic capacity constraints
• payer coverage variability across commercial vs Medicare Advantage vs Medicaid
• regional disparities in provider networks

What delivery and administration constraints typically cap adoption?

Psychedelic treatments often require structured administration and monitoring. That caps throughput per provider and can compress near-term adoption even when prescribing interest exists.

What drives QFITLIA demand: payer coverage, clinical differentiation, and patient flow?

QFITLIA demand is a function of coverage probability multiplied by eligible patient flow.

Payer levers that most influence QFITLIA volume

• prior authorization criteria strictness
• step therapy enforcement
• limits on number of treatment sessions per year
• preferred-provider contracting for centers capable of administration
• pharmacovigilance and REMS-like administrative requirements if applicable

Clinical differentiation that translates into coverage

Payers prioritize clinically meaningful endpoints that support durability and lower relapse rates, because those outcomes reduce repeat-treatment and downstream costs.

What are the major competitive threats to QFITLIA and how do they compare?

Competition in psychedelics and mental health biologics or small molecules tends to come from three directions:

1. other psychedelic approaches (psilocybin analogs, proprietary formulations)
2. non-psychedelic depression/anxiety therapies with better access economics
3. payer-favored lower-admin-cost regimens

How do competitors’ pricing and access strategies affect QFITLIA?

If alternative products are priced similarly but delivered through less constrained workflows, they can win formulary placement even with smaller efficacy differentials.

What substitution risk exists at the patient level?

Substitution risk rises when:

• payers deny coverage for QFITLIA but allow alternatives
• clinical protocols shift to other regimens
• adverse event management or monitoring burden increases provider resistance

What is QFITLIA pricing power and gross-to-net trajectory risk?

QFITLIA gross-to-net is likely to be pressured by:

• rebates and discounts required for formulary status
• administrative service costs associated with restricted access models
• contracting pressure from large PBMs and payer groups seeking utilization control

Why specialty contracting matters for net pricing

Specialty products sold through controlled distribution channels often face more concentrated payer leverage in early cycles. That can compress net price even if list price holds.

What is QFITLIA’s revenue trajectory under different adoption curves?

QFITLIA’s financial performance will typically track a staged S-curve:

• early cycle: limited access, slower volume ramp
• mid cycle: payer expansions and clinic network growth
• late cycle: potential plateau if competition or coverage tightening occurs

Scenario dynamics that typically change revenue slope

• payer expansion speed (faster ramps if denials fall)
• safety messaging and real-world outcomes
• provider network density
• manufacturing scale and supply stability

What patent and exclusivity issues affect QFITLIA’s long-term revenue?

Revenue duration risk in the psychedelic category can be driven by the combination of patent coverage for:

• active ingredient
• specific formulations or dosage forms
• manufacturing process
• method of treatment (indication and dosing regimen)

What patents protect QFITLIA and how broad is the estate?

QFITLIA’s patent estate strength determines whether generic or “next-generation” competitors face narrow design-around freedom or broader infringement barriers.

How to think about generic entry risk for QFITLIA

• If core patents cover the active ingredient in the relevant form and method, entry faces longer barriers.
• If exclusivity is tied to specific dosing regimens or clinic administration protocols, competitors may attempt label or regimen redesign.

What is the Orange Book status of QFITLIA and what does that imply for generic timing?

Orange Book listing status is the most direct indicator of:

• listed patents (drug substance, drug product, method of use)
• patent expiry and potential Paragraph IV routes

What generic launch scenarios are consistent with typical Orange Book patterns?

• Paragraph IV certification against method-of-use patents
• narrow launch limited to non-infringing strengths or regimens
• delayed launch if additional unexpired patents are asserted or listed

What biosimilar risk exists for QFITLIA?

Biosimilar risk is not usually relevant for small-molecule psychedelic drugs unless the product is biologic or involves biologically derived components. If QFITLIA is not a biologic, biosimilar pathways do not apply.

What QFITLIA patent litigation affects the business outlook?

Psychedelic product litigation, when it occurs, typically centers on:

• scope of method-of-use claims
• adequacy of notice for Paragraph IV challenges
• invalidity and non-infringement contentions

Settlement dynamics that can change revenue

Settlements can produce:

• delayed generic entry windows
• co-existence with label-limited generics
• license-based payments that affect net profitability

What FDA regulatory milestones and labeling changes matter for revenue?

Revenue trajectory is sensitive to:

• label expansion into additional populations or severity grades
• safety updates that affect administration protocols
• changes to required monitoring frameworks that alter cost of care

How regulatory updates can shift payer acceptance

If labeling becomes broader with clearer endpoints and manageable safety, payers may expand coverage. If safety risk perception increases, payers may tighten criteria.

How does QFITLIA’s commercial mix affect financial trajectory: specialty channel, payer mix, and setting costs?

Psychedelic therapy economics depend on the blend of:

• Medicare vs commercial patients
• in-network vs out-of-network clinics
• administration setting efficiency
• patient adherence and completion rates

What KPIs investors and buyers track

• new patient starts per month
• treatment completion and re-dosing rates
• denial rate and approval turnaround time
• net price after rebates and service-related offsets

Key Takeaways

• QFITLIA’s revenue ramp depends less on prescriber interest and more on payer coverage probability and clinic throughput constraints.
• Financial trajectory risk is concentrated in three areas: payer acceptance dynamics, competition and substitution, and IP/exclusivity durability that governs downstream generic or alternative-therapy entry.
• Long-term upside comes from label clarity and payer broadening; downside comes from coverage tightening, policy shifts, or patent-driven design-around opportunities.

FAQs

1. What payer coverage barriers most limit QFITLIA utilization in early launches?
2. How does clinic administration capacity influence QFITLIA adoption and revenue ramp?
3. What Orange Book patent categories usually drive the longest QFITLIA revenue protection?
4. What Paragraph IV challenge patterns are most likely for a psychedelic therapy product like QFITLIA?
5. Which competitor classes most threaten QFITLIA through substitution at the treatment-plan level?

References

1. APA-style references would be listed here, but no source material for QFITLIA’s approvals, Orange Book listings, or financial metrics was provided in the prompt.